Sylvia Adams

6PUBLICATIONS
15CO-AUTHORS
Predictive and prognostic markersMolecular targetsTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 26, 2023
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis.

Sherene Loi, Roberto Salgado, Peter Schmid

|Jun 07, 2021
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.

Hope S Rugo, Sherene Loi, Sylvia Adams

|Feb 01, 2021
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.

Leisha A Emens, Luciana Molinero, Sherene Loi

|Feb 10, 2018
Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.

Maryann J Kwa, Sylvia Adams

|Nov 11, 2017
Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.

Maryann Kwa, Xiaochun Li, Yelena Novik

Pageof 1

Frequent Collaborators

3 joint publications

Sherene Loi

3 joint publications

Hiroji Iwata

3 joint publications

Eric P Winer

2 joint publications

Hope S Rugo